Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease

被引：3
|
作者：
Nunez-Gomez, Laura [1 ]
Mesonero-Gismero, Francisco [1 ]
Albillos-Martinez, Agustin [1 ]
Lopez-Sanroman, Antonio [1 ]
机构：
[1] Hosp Univ Ramon y Cajal, Serv Gastroenterol & Hepatol, Madrid, Spain
来源：
GASTROENTEROLOGIA Y HEPATOLOGIA | 2018年 / 41卷 / 09期
关键词：
Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Anti-TNF; EVIDENCE-BASED CONSENSUS; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; EXTRAINTESTINAL MANIFESTATIONS; CLINICAL CHARACTERISTICS; PYODERMA-GANGRENOSUM; FACTOR ANTAGONISTS; NATURAL-HISTORY; INFLIXIMAB; FISTULAS;
D O I：
10.1016/j.gastrohep.2018.06.010
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Anti-tumor necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust. The aim of this review was to perform an analysis of the available literature and to determine the rote of anti-TNF drugs in common clinical practice in patients affected by these complications. (C) 2018 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码：576 / 582
页数：7
相关论文
共 50 条
  • [1] Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease
    Singh, Siddharth
    Pardi, Darrell S.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (03) : 457 - +
  • [2] Mechanisms of Action of Anti-tumor Necrosis Factor a Agents in Crohn's Disease
    Peake, Simon T. C.
    Bernardo, David
    Mann, Elizabeth R.
    Al-Hassi, Hafid O.
    Knight, Stella C.
    Hart, Ailsa L.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (07) : 1546 - 1555
  • [3] Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab
    Korzenik, JR
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (02) : 285 - +
  • [4] Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
    Laurie S. Conklin
    Bernard Cohen
    Lindsay Wilson
    Carmen Cuffari
    Maria Oliva-Hemker
    Nature Reviews Gastroenterology & Hepatology, 2010, 7 : 174 - 177
  • [5] Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
    Conklin, Laurie S.
    Cohen, Bernard
    Wilson, Lindsay
    Cuffari, Carmen
    Oliva-Hemker, Maria
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (03) : 174 - 177
  • [6] Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease
    Luis Cabriada, Jose
    Vera, Isabel
    Domenech, Eugeni
    Barreiro-de Acosta, Manuel
    Esteve, Maria
    Gisbert, Javier P.
    Panes, Julia
    Gomollon, Fernando
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (03): : 127 - 146
  • [7] The Use of Anti-Tumor Necrosis Factor Agents and Development of Psoriasis in Patients with Crohn's Disease
    Lin, Ming
    Blonski, Wojciech
    Weiner, Mark
    Tierney, Ann
    Marchioni, Renee
    Buchner, Anna
    Lichtenstein, Gary
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S490 - S491
  • [8] Anti-tumor necrosis factor therapy for ulcerative colitis
    Kountouras, J
    Zavos, C
    Chatzopoulos, D
    GASTROENTEROLOGY, 2005, 129 (03) : 1138 - 1139
  • [9] Anti-Tumor Necrosis Factor Nonresponders in Crohn's Disease: Therapeutic Strategies
    Louis, E.
    Belaiche, J.
    Reenaers, C.
    DIGESTIVE DISEASES, 2009, 27 (03) : 351 - 357
  • [10] Anti-tumor necrosis factor α:: Crohn's disease guided missile -: Comment
    Bitton, A
    INFLAMMATORY BOWEL DISEASES, 1998, 4 (02) : 173 - 174
12345